Fòrm PTO-1390	J.S. DEPARTMENT OF COMMERC	ATTORNEY'S DOCKET NUMBER					
.i 1	PATENT AND TRADEMARK OFFIC	P26459					
TRANSMITTAL LETTER TO DESIGNATED/ELECTED C							
CONCERNING A FILING U		U.S. APPLICATION NO (If known, see 37 CFR 1.5)					
INTERNATIONAL APPLICATION NO. PCT/KR2003/001279	INTERNATIONAL FILING DATE 28 June 2003	PRIORITY DATE CLAIMED 29 June 2002					
TITLE OF INVENTION: HANSENULA POLYMORPHA YAPSIN DEFICIENT MUTANT STRAIN AND PROCESS FOR THE PREPARATION OF RECOMBINANT PROTEINS USING THE SAME							
APPLICANT(S) FOR DO/EO/US Hyun-Ah KANG, Sang-Ki RHEE, Min-Jeong SOHN and Jeong-Yoon KIM							
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.							
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.							
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.							
3. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (23) indicated below.							
4. 🗵 The US has been elected (PCT Article 31).							
 5. ⊠ A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. ☐ is attached hereto (required only if not communicated by the International Bureau). b. ☒ has been communicated by the International Bureau. c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US). 							
6. ☑ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).							
a. ⊠ is attached hereto. b. ☐ has been previously submitted under 35 U.S.C. 154 (d) (4).							
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))							
 a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 							
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9. An oath or declaration of the inventor(s) (35 U.S.C371(c)(4)). (UNEXECUTED)							
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items 11 to 16 below concern other document(s) or information included:							
11. Assignee: Korea Research Institute of Bioscience and Biotechnology, of Daejeon, REPUBLIC OF KOREA, LeadBio, Inc., of Dajeon, REPUBLIC OF KOREA and BioHoldings Co., Ltd., of Dajeon, REPUBLIC OF KOREA.							
12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
14. ⊠ A FIRST preliminary amendment. ☐ A SECOND or SUBSEQUENT preliminary amendment.							
15. An Application Data Sheet under 37 C.F.R. 1.76.							
16. A substitute specification.							
17. A power of attorney and/or change of address letter.							
18. Figure of Drawing to be published: Fig. 5							
19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.							
20. A second copy of the published international application under 35 U.S.C. 154 (d) (4).							
21. A second copy of the English language translation of the international of the international application under 35 U.S.C. 154 (d) (4).							
22. ☑ Other items or information: International Application as published (including 14 pages of sequence listings). PCT/RO/101 PCT-Request with International Application as filed (including 14 pages of sequence listings). PCT/IB/308. PCT/ISA/210. PCT/IPEA/401 Chapter II Demand. PCT/IPEA/409 International Preliminary Examination Report. PCT/IB/304. PCT/IB/301. PCT/IB/302. PCT/IB/332. PCT/IPEA/402.							
Cover Letter under 35 U.S.C. 371 and 37 C.F.R. 1.495 Claim of Priority.							

DT01 Rec'd PCT/PTC 2 8 DEC 2004

			·		, 5001	
U.S. APPLICATION NO. (If known, see 37 INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER			
CFR 1.5)	518377	PCT/KR2003/001279		P26459		
101	710711	101/1(12005/001275		CALCULATIONS	PTO USE ONLY	
23 🗵 The following fe	es are submitted:			CALCOLATIONS	PIOUSEONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$ 0.00			
		or declaration later than	n 🗌 20 📋 30	\$ 0.00		
months from the earliest claimed priority date (37 CFR 1.492(e)). Basic National Stage Fee \$300.00			300.00			
National Stage Application Size Fee – for each additional 50 sheets				0.00		
that exceeds 100 sheets			\$250.00	0.00		
National Stage Search Fee			\$500.00	500.00		
National Stage Examination Fee			\$200.00	200.00		
Claims	Number Filed	Number Extra	Rate			
Total Claims	17 - 20 =	0	× \$50.00	\$ 0.00		
Independent Claims	3 - 3=	0	x \$200.00	\$ 0.00		
Multiple Dependent Cla	im(s) (if applicable)		+ \$360.00	\$ 0.00		
TOTAL OF ABOVE CALCULATIONS =			ALCULATIONS =	\$1,000.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.			\$ 0.00			
			SUBTOTAL =	\$1,000.00		
Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).			\$ 0.00			
Extension of Time fee in	Extension of Time fee in the amount of \$			\$ 0.00		
TOTAL NATIONAL FEE =			\$1,000.00			
Fee for recording the er be accompanied by an property	nclosed assignment (37 appropriate cover shee	7 CFR 1.21(h)). The ass et (37 CFR 3.28, 3.31).	signment must \$40.00 per	\$ 0.00		
TOTAL FEES ENCLOSED =			\$1,000.00			
,				Amount to be refunded	\$	
······································				Charged	\$	
		over the above fees is inin the amoun		o cover the above fees.		
	and Trademark Office to Deposit Account No	is hereby authorized to . 19-0089.	charge any addit	ional fees which may l	be required, or credit	
		WARNING: Information e included on this form			uthorization on PTO-	
		der 37 C.F.R. 1.16 and ition for extension of time				
		under 37 CFR 1.494 of ted to restore the appli		g status.		
SEND ALL CORRESPO	ONDENCE TO CUSTO	MER NO. 7055	Leslie J	. Papemer Zosl	Marener	
AT THE PRESENT AD			Rea No	33,329 SIGNATURE		
Bruce H. Bernstein			ricy. NC	,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
GREENBLUM & BERNSTEIN, P.L.C.				Bruce H. Bernstein		
1950 Roland Clark Place				NAME		
Reston, VA 20191 (703) 716-1191				29,027	_	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				REGISTRATION	NUMBER	

10 /5 18377 DT01 Rec'd PCT/FTC 2.8 DEC 2004

P26459

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hyun-Ah KANG et al.

Mail Stop PCT

Appl. No :Not Yet Assigned

(U.S. National Phase of PCT/KR2003/001279)

I.A.Filed: 28 June 2003

For

: HANSENULA POLYMORPHA YAPSIN DEFICIENT MUTANT STRAIN AND PROCESS FOR THE PREPARATION OF RECOMBINANT PROTEINS USING

THE SAME

COVER LETTER ACCOMPANYING U.S. NATIONAL STAGE PATENT APPLICATION FILED UNDER 35 U.S.C. 371 AND 37 C.F.R. 1.495

Mail Stop PCT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Enclosed is a new National Stage patent application for filing in the U.S. Patent and Trademark Office under 35 U.S.C. 371 and 37 C.F.R. 1.495. The Declaration and Power of Attorney attached thereto are in unexecuted form. A properly executed Declaration and Power of Attorney will be filed within the period of time set in a Notification to be mailed by the United States Patent and Trademark Office.

Related to the above, this application should be associated with Customer Number 7055, which includes the present correspondence address as follows:

GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 If there are any questions pertaining to this National Stage Application, please contact the undersigned.

Respectfully submitted, Hyun-Ah KANG et al.

Bruce H. Bernstein Reg. No. 29,027

Leslie J. Paperner

Reg. No. 33,329

December 28, 2004 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191